NYU Langone Health

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, NYU Langone Health sits in the top decile of US sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count).

1,164 total trials 197 currently recruiting 741 completed early-phase tilt top decile by trial count

NYU Langone Health: 1,164 sponsored US clinical trials, 197 recruiting.

NYU Langone Health sponsors 1,164 registered US clinical trials on ClinicalTrials.gov, 197 of them currently recruiting, and 741 completed. 123 of these trials are in Phase 3-4 (later-stage) and 231 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.

Top-decile sponsor footprint

NYU Langone Health ranks in the top decile of sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 53/100

741 of 866 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,164 total, page 20 of 24

TERMINATED Phase 1

Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer

NCT01677845
COMPLETED Phase 3

Prospective Trial of Two Prone Breast Radiotherapy Techniques With Randomization to Concurrent Versus Weekly Boost

NCT01591811
COMPLETED

Clinical Application of "Train of Four" Testing in the Intraoperative Monitoring Setting

NCT01932983
COMPLETED Phase 4

Screening for Coronary Artery Disease Using Fluoroscopy During Coronary Angiography

NCT01605045
COMPLETED NA

Starting Early Obesity Prevention Program

NCT01541761
COMPLETED Phase 4

Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery

NCT01901588
TERMINATED

Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)

NCT02237703
TERMINATED Phase 4

Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia

NCT01890694
COMPLETED NA

Music Therapy/Physical Therapy Intervention to Enhance Well-being and Functional Recovery Post-stroke

NCT01586221
COMPLETED Phase 1

Aprepitant Effects in Intravenous Heroin Dependence

NCT01527994
COMPLETED NA

Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital

NCT01483378
COMPLETED NA

The Resilience Alliance

NCT02521571
COMPLETED

Study of Gut Microbiome and Colorectal Tumors

NCT03297996
COMPLETED

Sleep Disordered Breathing and Alzheimer's Disease Biomarkers in Normal Aging and Mild Cognitive Impairment

NCT03912571
COMPLETED Phase 2

The Nutritional Supplement Phosphatidylserine in Patients With Familial Dysautonomia

NCT02276716
COMPLETED Phase 2

Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

NCT01419639
COMPLETED Phase 2

Safety Study of Pyridostigmine in Heart Failure

NCT01415921
TERMINATED Phase 2

Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma

NCT01438177
COMPLETED

Effects of Weight Loss on Cardio-respiratory Function

NCT01410487
TERMINATED Phase 2

Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

NCT01315873
TERMINATED Phase 4

Effect of Intravenous Ibuprofen on Inflammatory Responses in Patients Undergoing Surgery With General Anesthesia.

NCT01377441
COMPLETED Phase 1

Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases

NCT01421017
COMPLETED

Comparative Effectiveness of Bariatric Surgery Versus Medical Management to Induce Diabetes Remission in Diabetic Patients With BMI 30-35

NCT01423877
COMPLETED NA

Improving Parent Understanding of Instructions About Asthma Care

NCT01405625
COMPLETED Phase 4

Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia

NCT01901575
COMPLETED NA

Online Wound Electronic Medical Record (OWEMR) to Decrease Amputations in Diabetics

NCT01371318
COMPLETED NA

Effectiveness of Smoking-cessation Interventions for Urban Hospital Patients

NCT01363245
TERMINATED

Progression of Diabetic Retinopathy Post Bariatric Surgery (BS)

NCT01393873
COMPLETED NA

Ultrasound Imaging in Finding Prostate Cancer in Patients Undergoing Surgery

NCT02024178
COMPLETED

Comparison of Obesity Alleles Among Diverse Demographic Patients

NCT01396096
TERMINATED Phase 1

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor

NCT01372618
COMPLETED NA

LLLT Combined With CDT in Breast Cancer-Related Lymphedema

NCT01351376
TERMINATED Phase 2

Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas

NCT01338857
COMPLETED NA

Faith-based Approaches to Treating Hypertension and Colon Cancer Prevention

NCT01405638
TERMINATED NA

Device for Monitoring Pain During Intraoperative, Pre/Post Surgical Periods: Comparison With Standard of Care Monitoring

NCT02630134
TERMINATED Phase 2

A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma

NCT01302366
COMPLETED Phase 2

Preventive Approach to Congenital Heart Block With Hydroxychloroquine

NCT01379573
COMPLETED NA

Study of the Recovery of Muscle Function in the Arm/Hand After a Stroke

NCT01422005
COMPLETED

Brain Rhythms in Fibromyalgia: A Magnetoencephalography (MEG) Study

NCT02159300
COMPLETED

Women With Epilepsy: Pregnancy Outcomes and Deliveries

NCT01259310
COMPLETED NA

Faith-based Approaches in the Treatment of Hypertension (FAITH)

NCT01065831
COMPLETED Phase 2

CBT for Social Anxiety Disorder Delivered by School Counselors

NCT01320800
TERMINATED Phase 4

Safety and Efficacy of Direct Blood Volume Measurement in the Treatment of Heart Failure

NCT01001312
COMPLETED NA

Asian American Partnerships in Research and Empowerment (AsPIRE)

NCT03100812
COMPLETED

Using Nudges to Implement Comparative Effectiveness

NCT01575171
COMPLETED NA

Cyberknife for Early Stage Breast Cancer

NCT03946683
TERMINATED NA

Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion

NCT01377623
TERMINATED NA

A Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis

NCT02528097
COMPLETED NA

Speed of Processing Training in Traumatic Brain Injury

NCT02507271
COMPLETED Phase 4

Preventing Propofol Injection Pain: Prospective Randomized Trial Comparing Propofol Versus Fospropofol

NCT01401049
← Previous Page 20 of 24 Next →

Phase Distribution

PhaseTrial count
Phase 1 99
Phase 2 132
Phase 3 28
Phase 4 95

Therapeutic Areas

Prostate Cancer 12
Breast Cancer 11
Multiple Sclerosis 9
Hypertension 8
Cardiovascular Diseases 8
Attention Deficit Hyperactivity Disorder 7
Depression 7
Epilepsy 7
Opioid Use Disorder 7
Coronary Artery Disease 6

What is open in the NYU Langone Health pipeline

197 recruiting of 1,164 indexed (17% open); 741 completed (64%).

Phase mix: 123 late (III/IV) vs 231 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

NYU Langone Health: open-pipeline peers nationwide

Peers matched on 1,164 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 15%16%17%18%19% Total trials Recruiting share NYU Langone HealthUniversity of Alabama at BirminghamWake Forest University Health SciencesEmory UniversityNorthwestern UniversityCSL BehringPenn State UniversityUniversity of HawaiiUniversity of Utah
NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,164 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this NYU Langone Health page

1,164 registered trials is a research-attention snapshot, not an endorsement of NYU Langone Health or any single study.

  • 197 of NYU Langone Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition NYU Langone Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

NYU Langone Health pipeline card: 1,164 registered trials from official public datasets.Report a data error.